-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18

Benzinga·05/12/2026 16:22:15
Listen to the news
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and lowers the price target from $21 to $18.